BACKGROUND: Ependymoma is the most common glial tumor of the adult spinal cord. Current consensus recommends surgical resection with gross total resection (GTR) whenever possible. We performed a comprehensive review of the literature to evaluate whether adjuvant radiotherapy after subtotal resection (STR) has any benefit. METHODS: A PubMed search was performed to identify adult patients with spinal cord ependymoma who underwent surgical resection. Only patients who had clearly defined extent of resection with or without adjuvant radiotherapy were included for analysis. Kaplan-Meier and multivariate Cox regression survival analyses were performed to determine the effects of adjuvant radiotherapy on progression-free survival (PFS) and overall survival (OS). RESULTS: A total of 348 patients underwent surgical resection of spinal cord ependymomas, where GTR was obtained in 77.0% (268/348) of patients. Among those who received STR, 58.8% (47/80) received adjuvant radiotherapy. PFS was significantly prolonged among those who received adjuvant radiotherapy after STR (log rank; P < .001). This prolonged PFS with adjuvant radiotherapy remained significant in multivariate Cox regression analysis (STR versus STR + RT group; hazard ratio (HR) = 2.26, P = .047). By contrast, improved OS was only associated with GTR (GTR versus STR + RT group; HR = 0.07, P = .001) and benign ependymomas (HR = 0.16, P = .001). CONCLUSIONS: Surgery remains the mainstay treatment for spinal cord ependymomas, where GTR provides optimal outcomes with longest PFS and OS. Adjuvant radiotherapy prolongs PFS after STR significantly, and OS is improved by GTR and benign tumor grade only.
BACKGROUND:Ependymoma is the most common glial tumor of the adult spinal cord. Current consensus recommends surgical resection with gross total resection (GTR) whenever possible. We performed a comprehensive review of the literature to evaluate whether adjuvant radiotherapy after subtotal resection (STR) has any benefit. METHODS: A PubMed search was performed to identify adult patients with spinal cord ependymoma who underwent surgical resection. Only patients who had clearly defined extent of resection with or without adjuvant radiotherapy were included for analysis. Kaplan-Meier and multivariate Cox regression survival analyses were performed to determine the effects of adjuvant radiotherapy on progression-free survival (PFS) and overall survival (OS). RESULTS: A total of 348 patients underwent surgical resection of spinal cord ependymomas, where GTR was obtained in 77.0% (268/348) of patients. Among those who received STR, 58.8% (47/80) received adjuvant radiotherapy. PFS was significantly prolonged among those who received adjuvant radiotherapy after STR (log rank; P < .001). This prolonged PFS with adjuvant radiotherapy remained significant in multivariate Cox regression analysis (STR versus STR + RT group; hazard ratio (HR) = 2.26, P = .047). By contrast, improved OS was only associated with GTR (GTR versus STR + RT group; HR = 0.07, P = .001) and benign ependymomas (HR = 0.16, P = .001). CONCLUSIONS: Surgery remains the mainstay treatment for spinal cord ependymomas, where GTR provides optimal outcomes with longest PFS and OS. Adjuvant radiotherapy prolongs PFS after STR significantly, and OS is improved by GTR and benign tumor grade only.
Authors: Fadi Hanbali; Daryl R Fourney; Eric Marmor; Dima Suki; Laurence D Rhines; Jeffrey S Weinberg; Ian E McCutcheon; Ian Suk; Ziya L Gokaslan Journal: Neurosurgery Date: 2002-11 Impact factor: 4.654
Authors: Scott R Plotkin; Caroline C O'Donnell; William T Curry; Catherine M Bove; Mia MacCollin; Fabio P Nunes Journal: J Neurosurg Spine Date: 2011-02-04
Authors: N Fakhrai; P Neophytou; K Dieckmann; A Nemeth; D Prayer; J Hainfellner; C Marosi Journal: Acta Neurochir (Wien) Date: 2004-09-13 Impact factor: 2.216
Authors: Elizabeth Vera-Bolanos; Kenneth Aldape; Ying Yuan; Jimin Wu; Khalida Wani; Mary Jo Necesito-Reyes; Howard Colman; Girish Dhall; Frank S Lieberman; Philippe Metellus; Tom Mikkelsen; Antonio Omuro; Sonia Partap; Michael Prados; H Ian Robins; Riccardo Soffietti; Jing Wu; Mark R Gilbert; Terri S Armstrong Journal: Neuro Oncol Date: 2014-08-13 Impact factor: 12.300
Authors: Rupesh Kotecha; Minesh P Mehta; Eric L Chang; Paul D Brown; John H Suh; Simon S Lo; Sunit Das; Haider H Samawi; Julia Keith; James Perry; Arjun Sahgal Journal: Neuro Oncol Date: 2019-06-10 Impact factor: 12.300
Authors: Emma Celano; Arsalaan Salehani; James G Malcolm; Erik Reinertsen; Constantinos G Hadjipanayis Journal: J Neurooncol Date: 2016-05-06 Impact factor: 4.130
Authors: Eli T Sayegh; Derick Aranda; Joseph M Kim; Taemin Oh; Andrew T Parsa; Michael C Oh Journal: J Clin Neurosci Date: 2014-07-15 Impact factor: 1.961
Authors: Roberta Rudà; Guido Reifenberger; Didier Frappaz; Stefan M Pfister; Anne Laprie; Thomas Santarius; Patrick Roth; Joerg Christian Tonn; Riccardo Soffietti; Michael Weller; Elizabeth Cohen-Jonathan Moyal Journal: Neuro Oncol Date: 2018-03-27 Impact factor: 12.300